Related Experiment Videos
[Intermittent intravenous cyclophosphamide application in patients with systemic lupus erythematosus]
1Zavod za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti Medicinskog fakulteta i KBC-a Zagreb.
Lijecnicki Vjesnik
|August 8, 2009
Summary
Cyclophosphamide (CF) pulse therapy effectively treated lupus nephritis (LN) and central nervous system lupus. This retrospective analysis shows significant improvements in patient parameters with manageable complications.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Context:
- Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE).
- Cyclophosphamide (CF) pulse therapy is a treatment option for severe lupus nephritis.
- Retrospective analysis of patient data is crucial for evaluating treatment efficacy.
Purpose:
- To evaluate the efficacy and safety of intermittent cyclophosphamide (CF) pulse therapy in patients with lupus nephritis (LN).
- To analyze the impact of CF pulse therapy on renal function and disease activity markers.
- To identify complications associated with CF pulse therapy in SLE patients.
Summary:
- The study analyzed 30 patients with lupus nephritis (LN) treated with cyclophosphamide (CF) pulse therapy.
- Significant improvements in proteinuria, serum creatinine, creatinine clearance, ESR, ANF titer, and complement activity were observed.
- The majority of patients completing initial therapy showed sustained improvement, with infections being the most common complication.
Impact:
- Intermittent cyclophosphamide (CF) pulse therapy demonstrates a positive therapeutic effect on lupus nephritis (LN).
- This treatment can halt the progression of renal failure in SLE patients.
- Careful patient monitoring is essential for managing complications and ensuring treatment success.
Related Concept Videos
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...